

\$\$\$STN;HighlightOn= ***;HighlightOff=*** ;

Welcome to STN International! Enter x.x

LOGINID:ssspta1633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Jun 03 New e-mail delivery for search results now available
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11 Oct 24 BEILSTEIN adds new search fields
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on
STN
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT
NEWS 14 Nov 25 More calculated properties added to REGISTRY
NEWS 15 Dec 04 CSA files on STN
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17 Dec 17 TOXCENTER enhanced with additional content
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 20 Feb 13 CANCERLIT is no longer being updated
NEWS 21 Feb 24 METADEX enhancements
NEWS 22 Feb 24 PCTGEN now available on STN
NEWS 23 Feb 24 TEMA now available on STN
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 25 Feb 26 PCTFULL now contains images
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multife SDI results
NEWS 27 Mar 20 EVENTLINE will be removed from STN
NEWS 28 Mar 24 PATDPAFULL now available on STN
NEWS 29 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 30 Apr 11 Display formats in DGENE enhanced
NEWS 31 Apr 14 MEDLINE Reload
NEWS 32 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 33 Apr 21 Indexing from 1947 to 1956 being added to records in
CA/CAPLUS
NEWS 34 Apr 21 New current-awareness alert (SDI) frequency in
WPI/SDI/INDEX/WPIX
NEWS 35 Apr 28 RDISCLOSURE now available on STN
NEWS 36 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 37 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 38 May 15 Supporter information for ENCOMPAT and ENCOMPLIT
updated
NEWS 39 May 16 CHEMREACT will be removed from STN
NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:44:54 ON 21 MAY 2003

=> FIL BIOSIS EMBASE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'BIOSIS' ENTERED AT 16:45:03 ON 21 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:45:03 ON 21 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:45:03 ON 21 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s protein tyrosine phosphoryla? (3a) 36
L1 4 PROTEIN TYROSINE PHOSPHORYLA? (3A) 36

=> s l1 or PTP36 or PTP 36
L2 38 L1 OR PTP36 OR PTP 36

=> s l2 and (transgen? or knockout or disrupt? or deficie? or delet?)
L3 14 L2 AND (TRANSGEN? OR KNOCKOUT OR DISRUP? OR DEFICIE?
OR DELET?)

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 6 DUP REM L3 (8 DUPLICATES REMOVED)

=> d bib abs 1.
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2002:794361 CAPLUS
DN 137:305753
TI ***Transgenic*** mice containing ***PTP36*** tyrosine phosphatase
gene ***disruptions*** and uses in screening drug
IN Allen, Keith D.
PA USA
SO U.S. Pat. Appl. Publ., 30 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2002152493 A1 20021017 US 2001-5467 20011204
WO 2002045500 A2 20020613 WO 2001-US47566 20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-251796P P 20001206

AB The present invention provides ***transgenic*** mice comprising a
disruption in a ***PTP36*** tyrosine phosphatase gene and
methods for the characterization of ***PTP36*** tyrosine phosphatase
gene function. Specifically, the present invention provides
transgenic mice comprising mutations in a ***PTP36*** gene.
Such ***transgenic*** mice are useful as models for disease and for
identifying agents that modulate gene expression and gene function, and as
potential treatments for various disease states and disease conditions.

L4 ANSWER 2 OF 6 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS
INC.

AN 2002:369580 BIOSIS

DN PREV200200369580

TI Neuroplastic behavior at the ganglion level: Comparative studies between
(mRen2)27 and mRen2.Lewis models of hypertension.

AU Logan, Exazevia Montreal (1); Diz, Debra I.; Averill, David B.; Ferrario,
Carlos M.; Ganten, Detlev; Aileru, Azeez A. (1)

CS (1) Life Sciences, Winston Salem State University, 115 South Chestnut St.,
Winston-Salem, NC, 27101 USA

SO FASEB Journal, (March 22, 2002) Vol. 16, No. 5, pp. A875.

http://www.fasebj.org/ print

Meeting Info.: Annual Meeting of Professional Research Scientists on
Experimental Biology New Orleans, Louisiana, USA April 20-24, 2002
ISSN: 0892-6638.

DT Conference

LA English

AB Synaptic plasticity in superior cervical ganglia isolated from
hypertensive (mRen2)27 ***transgenic*** rats is increased relative to
Hannover Sprague-Dawley rats, as measured by decay time constants of
post-tetanic potentiation (PTP) and long-term potentiation (LTP) after a
tetanizing volley (20Hz/20s) in the presence of hexamethonium. A new line
of congenic hypertensive rats, developed by transferring the mouse renin
gene to the inbred Lewis background (mRen2.Lewis), is hypertensive and has
many but not all the same characteristics of the parent strain.
Angiotensin II (16nM) increases the internal carotid nerve compound action
potential by 14% in (mRen2)27 and by 8% in mRen2.Lewis animals. After a
tetanic pulse, PTP and LTP were significantly longer (***PTP***
36 min, LTP: 1.03X103 min; n=8) in (mRen2)27 than mRen2.Lewis

(PTP: 15 min, LTP: 255 min; n=7) rats. The mechanisms responsible for these disparities in transmission are not known, but the data suggest that we can dissociate ganglionic changes occurring during sustained high blood pressure from those related to genetic differences in synaptic plasticity using these two strains of animals.

L4 ANSWER 3 OF 6 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1

AN 2000:228674 BIOSIS

DN PREV200000228674

TI Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases: Rapid Communication.

AU Reiser, Jochen (1); Pixley, Fiona J.; Hug, Andreas; Kriz, Wilhelm; Smoyer, William E.; Stanley, E. Richard; Mundel, Peter

CS (1) Department of Medicine and Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY USA

SO Kidney International, (May, 2000) Vol. 57, No. 5, pp. 2035-2042.

ISSN: 0085-2538.

DT Article

LA English

SL English

AB Background: Effacement of podocyte foot processes occurs early in many glomerular diseases associated with proteinuria and is accompanied by a reorganization of the actin cytoskeleton. The molecular mechanisms regulating these structural changes are poorly understood. Methods: To address these questions, we analyzed the effect of the polycation, protamine sulfate (PS), and puromycin aminonucleoside (PA) on the morphology, cytoskeleton, and tyrosine phosphorylation of differentiated process-bearing cultured podocytes. Results: PS and PA induced similar profound morphological alterations, including retraction and detachment of podocyte processes from the extracellular matrix (ECM). The effects of PS occurred within six hours, whereas PA showed its most severe effects after 72 hours. Structural changes included reorganization of the actin cytoskeleton and focal contacts and were accompanied by an increase in tyrosine phosphorylation. The same effects were induced by application of vanadate, an inhibitor of protein tyrosine phosphatases (PTPs), suggesting that PTPs regulate podocyte process structure. Since "disruption" of the actin cytoskeleton with cytochalasin B protected the cells from PS-induced effacement and detachment, cytoplasmic PTPs were implicated in these events. Using reverse transcription-polymerase chain reaction (RT-PCR), we demonstrated the expression of four cytoplasmic PTPs in podocytes: SHP-2, PTP-PEST, PTP-1B, and "PTP" . "36" . Conclusions: These studies indicate an important role for cytoplasmic PTPs as regulators of podocyte process dynamics. Future studies will aim at restoring the normal foot process architecture of podocytes in glomerular diseases associated with proteinuria by modulating the activity of cytoplasmic PTPs.

L4 ANSWER 4 OF 6 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2

AN 2000:296971 BIOSIS

DN PREV200000296971

TI Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling.

AU Han, Shulin; Williams, Scott; Mustelin, Tomas (1)

CS (1) Laboratory of Signal Transduction, La Jolla Cancer Research Center, Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037 USA

SO European Journal of Immunology, (May, 2000) Vol. 30, No. 5, pp. 1318-1325.

print.

ISSN: 0014-2980.

DT Article

LA English

SL English

AB The subgroup of protein tyrosine phosphatases that contain an N-terminal ezrin-, radixin- and moesin homology (ERM) domain and a C-terminal catalytic domain is represented by three enzymes in Jurkat T cells, PTPH1, PTP-MEG1 and "PTP36" . These enzymes are located at the cytoplasmic face of the plasma membrane and may be involved in regulation of the membrane cytoskeleton, signal transduction, or both. Here we report that expression of PTPH1 in Jurkat T cells reduced the TCR-induced activation of reporter genes encompassing parts of the IL-2 gene promoter and driven by nuclear factor of activated T cells plus activator protein-1. PTP-MEG1 had a weaker inhibitory effect, while "PTP36" had none. The catalytically inactive mutants PTPH1-CS and PTP-MEG1-CS lacked effects on gene transcription. Expression of active PTPH1 also reduced receptor-induced activation of Erk2 MAP kinase, its upstream activator, Mek, and the Jnk kinases. The effect of PTPH1 was reduced by "deletion" of its N-terminal ERM domain. We suggest that PTPH1 inhibits T cell activation by dephosphorylating membrane-associated targets involved in TCR signaling.

L4 ANSWER 5 OF 6 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 3

AN 1999:467437 BIOSIS

DN PREV199900467437

TI Regulation of phosphorylation level and distribution of "PTP36" , a putative protein tyrosine phosphatase, by cell-substrate adhesion.

AU Ogata, Masato (1); Takada, Tsuyoshi; Mori, Yoshiko; Uchida, Yohzo; Miki, Tsuneharu; Okuyama, Akihiko; Kosugi, Atsushi; Sawada, Motoyuki; Oh-hora, Masatsugu; Hamaoka, Toshiyuki

CS (1) Biomedical Research Center, Osaka University Medical School C6, 2-2 Yamadaoka, Suita, Osaka, 565-0871 Japan

SO Journal of Biological Chemistry, (July 16, 1999) Vol. 274, No. 29, pp.

20717-20724.

ISSN: 0021-9258.

DT Article

LA English

SL English

AB Recently we have cloned a putative protein tyrosine phosphatase, "PTP36" /PTPD2/pez, which possesses a domain homologous to the N-terminal half of band 4.1 protein. In mouse fibroblasts adhered to substrates, "PTP36" was phosphorylated on serine residues. "PTP36" was found to make complexes with serine/threonine kinase(s), which phosphorylated "PTP36" in vitro. "PTP36" was dephosphorylated rapidly when the cell-substrate adhesion was "disrupted" and it was phosphorylated again along with the reattachment of the cells to fibronectin. Rephosphorylation of "PTP36" seemed to depend on actin polymerization since it was inhibited by cytochalasin D. The cell detachment also induced the translocation of "PTP36" into the membrane-associated cytoskeletal fraction. Staurosporine and ML-9, which inhibited the phosphorylation of "PTP36" in vivo, induced the translocation of "PTP36" too. On the contrary, when the dephosphorylation of "PTP36" was inhibited by okadaic acid, no translocation of "PTP36" was induced by the cell detachment. These results demonstrate that the cell-substrate adhesion and cell spreading regulates the intracellular localization of "PTP36" most likely through its phosphorylation and therefore, "PTP36" may play important roles in the signal transduction pathway of cell-adhesion.

L4 ANSWER 6 OF 6 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 4

AN 2000:88313 BIOSIS

DN PREV20000088313

TI Characterization of newly identified four isoforms for a putative cytosolic protein tyrosine phosphatase "PTP36" .

AU Aoyama, Koji; Matsuda, Tsukasa; Aoki, Naohito (1)

CS (1) Department of Applied Molecular Biosciences, Graduate School of Biocultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601 Japan

SO Biochemical and Biophysical Research Communications, (Dec. 20, 1999) Vol. 266, No. 2, pp. 523-531.

ISSN: 0006-291X.

DT Article

LA English

SL English

AB In the course of determining the expression profiles of protein tyrosine phosphatases in lactating mammary gland, we found the expression of an isoform for a putative cytosolic and cytoskeleton-associated protein tyrosine phosphatase "PTP36" . Further detailed RT-PCR and Northern blot analyses revealed the expression of several isoforms for "PTP36" in a tissue-dependent manner. We have cloned the cDNAs encoding four truncated isoforms for "PTP36" and designated "PTP36" -A, -B, -C, and -D, respectively. "PTP36" -A and -C had new sequences generated due to frameshift, whereas "PTP36" -B and -D were in-frame variants. Gly- and Glu-rich domains and a putative PTP domain were missing from "PTP36" -A, but the band 4.1 domain remained. "PTP36" -B retained the band 4.1 and PTP domains but lacked Pro-, Gly- and Glu-rich domains. Most domain structures were lacking in "PTP36" -C and -D. Interestingly, "PTP36" -C contained an incomplete band 4.1 domain, but the newly created sequence exhibited high homology to human nebulin, which was also suggested to associate with cytoskeletons. When transiently expressed in COS7 and HEK293 cells, not only the wild type but also all the isoforms were recovered in Triton X-100-insoluble cytoskeleton-associated fractions and this distribution was not affected by mechanical cell detachment and treatment with a kinase inhibitor staurosporine. Such cellular distribution of "PTP36" was also observed in stable COS7 clones. Further studies using "deletion" mutants suggested that the first 30 amino acids as well as the band 4.1 domain of "PTP36" were involved in association with Triton X-100 insoluble cytoskeletons. Tissue-dependent expression and "deletion" in domain structures might reflect the biological significance of the isoforms for "PTP36" in certain physiological conditions.

=>

--Logging off of STN--

=>

Executing the logoff script..

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	36.75	36.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
TOTAL		
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-0.65	-0.65

STN INTERNATIONAL LOGOFF AT 16:48:07 ON 21 MAY 2003